Actym Therapeutics

Biotech company developing next-generation immunotherapeutic modalities that target solid tumors. The company’s platform is called STACT (Salmonella Typhimurium-Attenuated Cancer Therapy) and is an engineered, non-virulent payload delivery system that leverages the naturally high enrichment of bacteria in the tumor microenvironment (TME) to provide tumor-specific delivery.